Background Combining targeted therapy has been extensively investigated in previously
treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

In patients with advanced non-small cell lung cancer (NSCLC), the benefit-to-risk ratio of
doublet-targeted agents versus single agent is not clear. A systematic review and …

Introduction The introduction of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …

We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …

The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …

Background Currently, targeted therapy has shown encouraging treatment benefits in
selected patients with advanced non-small cell lung cancer (NSCLC). However, the …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …

Background: To determine the efficacy and safety of anti-angiogenic drugs combined with
erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC), we performed a …

Purpose The epidermal growth factor receptor (EGFR) is one of the four human epidermal
receptors. The efficacy and safety of EGFR-targeted therapies for treating non-small-cell …